AT10

AT10 is a proprietary, AAV (adeno-associated virus) vector-based gene therapy platform developed by the South Korean pharmaceutical company Reyon Pharm (이연제약). Currently in the preclinical stage, the platform is designed to optimize the delivery and expression of therapeutic genes, leveraging Reyon Pharm's specialized infrastructure for high-purity plasmid DNA (pDNA) and viral vector production at their Chungju facility. AT10 serves as a foundational technology for the company's internal and collaborative R&D programs, aimed at developing next-generation treatments for various genetic and chronic diseases. While specific molecular targets or lead indications for the AT10 platform have not been publicly detailed, it is a core component of Reyon Pharm's strategic expansion into the advanced biopharmaceutical market.

Other names

Gene therapy platform (AT10)AT10 gene therapy platformAT-10 gene therapy platformAT 10 gene therapy platform